Riskpilot← Back to searchSign inGet full accessDR.DROPIN SPESIALIST AS
ASActiveOrg 927782324Sørkedalsveien 8A, 0369 OsloMedical specialists activities · NACE 8622Est. 202112 employees
Revenue 2024
NOK 37,7M
+17% vs 2023
EBITDA margin
-10.1%
+76% vs 2023
Equity ratio
26.4%
Financial strength
Net profit 2024
NOK -5,4M
+61% vs 2023
| Revenue | NOK 37,7M | +17% |
| EBITDA | NOK -3,8M | +76% |
| Net profit | NOK -5,4M | +61% |
| Total assets | NOK 35,4M | -13% |
| Equity | NOK 9,3M | -37% |
| Employees | 12 | — |
Legal name
DR.DROPIN SPESIALIST AS
Org number
927782324
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
21. september 2021
Share capital
NOK 80 069
Employees
12 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Å investere i og å rådgi ulike selskaper.
Address
Sørkedalsveien 8A, 0369 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 14 856 | 32 254 | 37 711 |
| Staff expenses | −0 | −15 328 | −32 141 | −27 619 |
| EBITDA | −6 | −10 741 | −15 780 | −3 814 |
| Depreciation & amort. | −0 | −144 | −1 289 | −2 395 |
| EBIT | −6 | −10 886 | −17 069 | −6 209 |
| Net financials | 0 | −226 | −525 | −727 |
| Profit before tax | −6 | −11 111 | −17 594 | −6 935 |
| Tax | −0 | −2 444 | −3 867 | −1 526 |
| Net profit | −6 | −8 667 | −13 727 | −5 410 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 24 | 52 398 | 40 708 | 35 439 |
| Equity | 24 | 30 245 | 14 752 | 9 342 |
| Long-term debt | 0 | 0 | 1 950 | 1 350 |
| Short-term debt | 0 | 22 153 | 24 006 | 24 747 |
| Total debt | 0 | 22 153 | 25 956 | 26 097 |
EBITDA margin
-10.1%
This company
15.8%
Market median
-164% vs market
20212024
Equity ratio
26.4%
This company
38.2%
Market median
-31% vs market
20212024
Return on equity
-57.9%
This company
18.4%
Market median
-415% vs market
20212024
Net profit margin
-14.3%
This company
8.1%
Market median
-277% vs market
20212024
Asset turnover
1.06×
This company
1.12×
Market median
+5% vs market
20212024
Debt / equity
2.79×
This company
0.62×
Market median
-350% vs market
20212024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Former (2) | ||
| Chairman | 2021 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 94.57% | 94.57% | 2024 | |
| Company | 26.5% | 26.5% | 2023 | |
Krishna Dermatology Limited | Company | 1.56% | 1.56% | 2024 |
| Individual | 1.33% | 1.33% | 2022 | |
Sreedhar Krishna | Company | 1.12% | 1.12% | 2023 |
James Denny | Company | 1.09% | 1.09% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ledang Health As
DR.DROPIN SPESIALIST AS Board members of DR.DROPIN SPESIALIST AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Martin Schütt | Board of Directors | 0 companies |
| Håvard Liltved Dalen | Board of Directors | 0 companies |
| Martin Lycke | Chairman | 0 companies |
| Kristoffer Ingebrigtsen | Chairman | 0 companies |
| Karl-Axel Hjorth Bauer | Board of Directors | 0 companies |